Esophageal cancer: Clinical Practice Guidelines in oncology™

Jaffer Ajani, Tanios Bekaii-Saab, Thomas A. D'Amico, Charles Fuchs, Michael K. Gibson, Melvyn Goldberg, James A. Hayman, David H. Ilson, Milind Javle, Scott Kelley, Robert C. Kurtz, Gershon Yehuda Locker, Neal J. Meropol, Bruce D. Minsky, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Jack Roth, Aaron R. Sasson, Stephen G. SwisherDouglas E. Wood, Yun Yen

研究成果: 雜誌貢獻文章同行評審

25 引文 斯高帕斯(Scopus)


Esophageal cancer is a major health hazard in many parts of the world. The incidence of adenocarcinoma is increasing in white men, particularly in the nonendemic areas such as North America and many Western European countries. Barrett's metaplasia, gastroesophageal reflux, hiatal hernia, and obesity are believed to be contributing factors. In addition, the most common location of esophageal carcinoma has shifted to the lower third of the esophagus. Unfortunately, esophageal carcinoma is often diagnosed late and, therefore, most therapeutic approaches are palliative. Advances have been made in staging procedures and therapeutic approaches. The guidelines emphasize that palpable advances have been made in the treatment of locoregional esophageal carcinoma. Similarly, endoscopic palliation of esophageal carcinoma has improved substantially because of improving technology. New chemotherapeutic agents are on the horizon, including antireceptor agents, vaccines, gene therapy, and anti-angiogenic agents. The panel expects numerous future advances in the treatment of esophageal carcinoma.
頁(從 - 到)328-347
期刊JNCCN Journal of the National Comprehensive Cancer Network
出版狀態已發佈 - 4月 2006

ASJC Scopus subject areas

  • 腫瘤科


深入研究「Esophageal cancer: Clinical Practice Guidelines in oncology™」主題。共同形成了獨特的指紋。